Posted by Michael Wonder on 10 Feb 2026
US FDA accepts new drug application and grants priority review for Takeda’s oveporexton (TAK-861) as a potential first in class therapy for narcolepsy type 1
10 February 2026 - Takeda today announced that the US FDA accepted its new drug application and granted priority review for oveporexton (TAK-861) for the treatment of narcolepsy type 1.
The FDA has set a PDUFA goal date in the third quarter of this calendar year.
